News and Events from TessArae, LLC
Kazerin-based GGA designed the chip with TessArae, a Potomac Falls, Va.-based company that develops targeted sequencing applications for human genetic disease and microbial identification. GGA and TessArae have been working on the array for several years. Read more in BioArray News (subscription required).
Come visit us at booth #211 March 28-30th and learn about our GeneCipher™ targeted sequencing assays. Click here for more details: http://bit.ly/GFP2bm TessArae GeneCipher™ targeted sequencing assays provide unmatched performance for genetic disease testing in a microarray-based format. Through proprietary assay design and analysis algorithms, TessArae gives you the power to perform comprehensive carrier screening […]
POTOMAC FALLS, Va., June 8, 2011 /PRNewswire/ — TessArae®, LLC, a privately held company, today announced that it has appointed Tom Richards as its new President. Dr. Richards has held faculty positions at Stanford University Medical Center and UCSF Medical Center, where he currently practices as an Assistant Clinical Professor in the Department of Emergency […]
Come and visit us at booth 120 at the 2011 ACMG meeting in Vancouver, BC Canada. Learn about our GeneCipher™ Assay for genetic disease testing. More information at the ACMG Conference Website.
Dr. Matthew Lorence, Vice President, Marketing and Sales for Tessarae, LLC will chair the Growth in Personalized Cancer Diagnostics session of the Cancer Molecular Markers program at Molecular Med Tri-Con 2011. The session will be Friday February 25, 2011 at the Moscone North Convention Center, San Francisco, CA at 8:30am. 18th International Molecular Medicine Tri-Conference – […]
TessArae® was awarded a contract from the Massachusetts Department of Public Health for the purchase of DNA instrumentation, supplies, with support for validation, bioinformatics integration and training. TessArae is a private company that designs and delivers the most cost-effective, highly multiplexed, targeted DNA sequencing diagnostics available on the market today, providing solutions for two key […]
Expanding its activities in the genetic testing market, TessArae has partnered with an Israeli firm to design a resequencing microarray that can detect specific disease-causing mutations in 11 cancer genes. Kazerin-based Galil Genetic Analysis will next month launch the Affymetrix-made chip, according to officials from both companies. GGA CEO Yoram Plotsky told BioArray News this […]
Dr. Klaus Schafer, President and CEO of TessArae, has been selected to serve on the board of directors of the Virginia Biotechnology Association. The Virginia Biotechnology Association (VABIO), formed in 1992, is the premier statewide non-profit trade association representing the life sciences industry in the Commonwealth of Virginia. Nearly 200 member organizations have joined forces […]
TessArae will be in attendance at the 60th Annual Meeting of the American Society of Human Genetics meeting in Washington, DC on November 2-6, 2010. If you would like to speak to us, please contact us at: http://www.tessarae.com/contact.html. The TessArae Resequencing Diagnostic Microarray technology will also be discussed in a poster by Galil Genetic Analysis […]
TessArae Targeted Resequencing at GeneDx Provides More Comprehensive Analysis, Lower Cost, and Faster Results GeneDx is a premier genetic testing company that specializes in rare hereditary disorders. In 2008 the scientific team determined that they needed to update their testing method for Noonan Syndrome to enhance their competitive position in the market, and engaged in […]